Vinge has advised Amer Sports, Inc. in connection with its listing on the NYSE with credit facilities and issuance of bonds

March 26, 2024

Vinge has advised Amer Sports, Inc. in connection with the listing of the company on the New York Stock Exchange with 105,000,000 shares at a value of USD 1.37 billion, whereby Vinge has assisted Amer Sports, Inc. and its subsidiaries with regulatory matters and the establishment of credit facilities of USD 500 million and EUR 700 million respectively and with the issuance of USD 800 million senior secured bonds where the Swedish subsidiaries have provided certain guarantees.

Amer Sports is a global group of iconic sports and outdoor brands, including Arc'teryx, Salomon, Wilson, Peak Performance and Atomic. Amer Sports has over 10,800 employees and operates in 41 countries.


Vinge's team consisted of Fredrik Wilkens, Henrik Schön, David Flodin, Linn Adelwald, Arvid Weimers and Jolinn Uhlin.


Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024